Optionele productanalyse
Met uw toestemming gebruiken we privacyvriendelijke, beperkte analyses om te begrijpen welke onderzoeksroutes werken. We gebruiken geen advertentietrackers of sessieopnamen. U kunt deze keuze wijzigen in Voorkeuren. Lees het Privacybeleid.
Amgen Inc.'s published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $236.4B | |
|---|---|---|
| Revenue (ttm) | 38.1B | |
| Net income (ttm) | 8.7B | |
| EPS (ttm) | $16.1 | |
| Shares out | 540.6M | |
| P/E (trailing) | 28.1x | |
| P/E (forward) | 18.2x | |
| Dividend | $10.1 (2.23%) | |
| Volume | 2,016,147 | |
| Beta | 0.41 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $25.98B | $26.32B | $28.19B | $33.42B | $36.75B | +9.1% |
| Gross profit | $19.53B | $19.92B | $19.74B | $20.57B | $26.01B | +7.4% |
| Operating income | $7.64B | $9.57B | $7.90B | $7.26B | $9.08B | +4.4% |
| Net income | $5.89B | $6.55B | $6.72B | $4.09B | $7.71B | +7.0% |
| EPS (diluted) | $10.28 | $12.11 | $12.49 | $7.56 | $14.23 | +8.5% |
| EBITDA | $11.30B | $12.17B | $7.90B | $13.36B | $16.90B | +10.6% |
| R&D | $6.32B | $4.43B | $4.78B | $5.96B | $6.97B | +2.5% |
| SG&A | $5.37B | $5.41B | $6.18B | $7.10B | $7.05B | +7.1% |
Recent company headlines from major financial publishers.
Moderate growth and continued cash backing support the central valuation outlook. Evidence should emerge by FY2027 through annual revenue and adjusted EPS delivery.
Stronger revenue, earnings, and cash would extend growth duration without requiring a hyper-growth assumption. A low-end FY2027 earnings result would disconfirm this path.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 5.6% | $582 | $623 | $679 | $763 | $906 |
| 6.6% | $509 | $532 | $561 | $599 | $651 |
| 7.6% | $461 | $475 | $492 | $513 | $540 |
| 8.6% | $426 | $435 | $447 | $460 | $476 |
| 9.6% | $399 | $406 | $414 | $423 | $433 |
Upcoming earnings date and setup when available.
De rating die de gepubliceerde researcheditie van elke maand droeg. Een rating vergelijkt de koers op de analysedatum met de fair value; het is geen overzicht van of de inschatting juist bleek.
| Jaar | jan | feb | mrt | apr | mei | jun | jul | aug | sep | okt | nov | dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
